Clinical trials: CHD
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Congenital Heart Disease
Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
This study will test the capability of a non-invasive instrument (the PhysioFlow impedance cardiography instrument) to measure cardiac output in patients with congenital heart disease (CHD).
- Trial name
- NCT02326649
- Testing
- Physioflow
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Diego
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Coronary Heart Disease (CHD)
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
- Trial name
- GOLDILOX (NCT04610892)
- Testing
- MEDI6570
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
To Evaluate and Compare the Efficacy and Safety of Ezetimibe Plus Atorvastatin Versus Atorvastatin in Hypercholesterolemic Patients at High Risk for Coronary Heart Disease Not Adequately Controlled on Atorvastatin 40 mg.
- Trial name
- NCT00276484
- Testing
- atorvastatin, ezetimibe
- Volunteers
- 579 people
- Sponsor
- Organon and Co
Stable Coronary Heart Disease (CHD)
Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease
- Trial name
- NCT02064985
- Testing
- Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
- Where
- China
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately…
- Trial name
- NCT00276458
- Testing
- Comparator: atorvastatin, Comparator: ezetimibe
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Arterial Hypertension, CHD - Coronary Heart Disease
Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril
Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.
- Trial name
- STYLE (NCT03730116)
- Testing
- bisoprolol/perindopril FDC
- Where
- Russia
- Volunteers
- 1,909 people
- Sponsor
- Servier Russia
Respiratory Syncytial Virus Infections
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.
- Trial name
- JUBILUS (NCT06042049)
- Testing
- Nirsevimab
- Where
- 9 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Obesity, Weight Loss
Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)
Although coronary heart disease (CHD) treatment guidelines recognize obesity as a major modifiable risk factor,2 nearly half of all CHD patients are obese and the current standard of care fails to implement evidence-based obesity…
- Conditions
- Obesity, Weight Loss, CHD - Coronary Heart Disease
- Trial name
- TOPCARE (NCT03423238)
- Testing
- Exercise, Health Education, Exercise Compliance
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Hypercholesterolemia
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of…
- Trial name
- NCT00418834
- Testing
- ezetimibe and atorvastatin, atorvastatin
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Hearing Loss, Sensorineural
The EarLens Contact Hearing Device (CHD) Spectrum Study
The EarLens System is an assistive hearing device that is intended to provide amplification for the treatment of patients with sensorineural hearing impairment.
- Trial name
- Spectrum (NCT02470494)
- Testing
- Sound amplification provided via the EarLens CHD
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- EarLens Corporation
Hypercholesterolemia, Coronary Heart Disease
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- GRAVITY (NCT00525824)
- Testing
- Rosuvastatin (Crestor), Ezetimibe, Simvastatin
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 1,743 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
Assessmet of Patients With PAH Right Ventricular Volume
The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with…
- Trial name
- NCT01557582
- Testing
- Ventripoint Medical System
- Where
- 7 sites in United States, Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VentriPoint Diagnostics Ltd.
Hypercholesterolemia, Dyslipidemia
Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.
- Conditions
- Hypercholesterolemia, Dyslipidemia, Coronary Heart Disease
- Trial name
- NCT00344175
- Testing
- pitavastatin, simvastatin
- Where
- 28 sites in Denmark, Netherlands and 2 more
- Volunteers
- 178 people
- Sponsor
- Kowa Research Europe
Hepatitis D, Chronic
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD).
- Trial name
- NCT02732639
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a
- Where
- 7 sites in Romania
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Stable Angina, Coronary Disease
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
This study of 402 cases of stable angina subjects who were diagnosed as Coronary Heart Disease (CHD) is a randomized, blank controlled, multi-center clinical study.
- Trial name
- SIGMART (NCT01396395)
- Testing
- Nicorandil, Standard Treatment
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Coronary Artery Disease
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
The study will assess the regression of yellow plaque content of the lipid pool after aggressive lipid therapy by utilizing NIR spectroscopy.
- Trial name
- YELLOW (NCT01567826)
- Testing
- standard of care lipid therapy, Aggressive lipid therapy
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Annapoorna Kini